Amicus Therapeutics (NASDAQ:FOLD) has tumbled 7.11% during the past week and has dropped 17.84% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 5.99%. Amicus Therapeutics (NASDAQ:FOLD) has underperformed the index by 18.59% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Amicus Therapeutics (NASDAQ:FOLD): The stock opened at $6.03 on Friday but the bulls could not build on the opening and the stock topped out at $6.06 for the day. The stock traded down to $5.61 during the day, due to lack of any buying support eventually closed down at $5.62 with a loss of -6.18% for the day. The stock had closed at $5.99 on the previous day. The total traded volume was 4,696,087 shares.
The company shares have dropped -59.63% from its 1 Year high price. On Aug 5, 2015, the shares registered one year high at $18.83 and the one year low was seen on Feb 12, 2016. The 50-Day Moving Average price is $6.76 and the 200 Day Moving Average price is recorded at $7.56.
On the companys insider trading activities, Rosenberg Ellen, officer (General Counsel & Corp. Secy) of Amicus Therapeutics Inc, executed a transaction worth $115,050 on June 2, 2016. A total of 15,000 shares were purchased at an average price of $7.67. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Many analysts have stated their opinion on the company shares. Bank of America initiates coverage on Amicus Therapeutics (NASDAQ:FOLD) The current rating of the shares is Buy. Equity Analysts at the Firm announces the price target to $10 per share. The rating by the firm was issued on May 18, 2016. Currently the company Insiders own 8.3% of Amicus Therapeutics shares according to the proxy statements.
Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (SDs). The Companys lead product candidate is the pharmacological chaperone migalastat HCl (Galafold), a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Companys development programs also include ERTs for LSDs, including Fabry disease, Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Companys programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as ERT products for Fabry disease, Pompe disease and MPS I.